The FDA has approved Monjuvi (tafasitamab-cxix) for use in combination with lenalidomide and rituximab to treat adults with relapsed or refractory follicular lymphoma.

Research presented at ASCO 2025 highlighted potential treatments for patients with newly diagnosed and relapsed or refractory ...

Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for ...

PTCy plus cyclosporine proved more effective than standard GVHD prophylaxis in patients undergoing matched sibling PBSCT in a phase 3 trial.

The program significantly shortens the FDA review time for a sponsor's final drug application submission from approximately 10-12 months to 1-2 months.

An HHS document intended to support the department's change in COVID-19 vaccine policy cites studies that are unpublished or ...

Colorectal cancer highlights from ASCO 2025 include findings from the BREAKWATER, ATOMIC, DYNAMIC-III, and TRIPLETE trials.

Adding lurbinectedin to atezolizumab as first-line maintenance improved PFS and OS in patients with ES-SCLC in the phase 3 ...

Source: Getty Images "[W]e dissent to Administration policies that undermine the NIH mission, waste public resources, and ...

Children with non-germinomatous germ cell tumors may have better IQ recovery if they receive proton radiotherapy rather than photon radiotherapy.

A survey of more than 20,000 patients revealed a lack of trust in information about cancer, whether it comes from scientists, doctors, or other sources.

Targeted therapies and immunotherapy can provide benefits when added to chemotherapy or may eliminate the need for chemotherapy in certain patients with NSCLC.